Purple Biotech Ltd. (PPBT)
3.64
-0.14 (-3.70%)
At close: Jan 14, 2025, 3:59 PM
3.62
-0.55%
Pre-market Jan 15, 2025, 04:03 AM EST
undefined% (undefined)
| Bid | 3.54 |
| Market Cap | 9.41M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -8.1 |
| PE Ratio (ttm) | -0.45 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.74 |
| Volume | 44,266 |
| Avg. Volume (20D) | 954,573 |
| Open | 3.68 |
| Previous Close | 3.78 |
| Day's Range | 3.55 - 3.87 |
| 52-Week Range | 2.00 - 20.60 |
| Beta | undefined |
About PPBT
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and panc...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 20, 2015
Employees 20
Stock Exchange NASDAQ
Ticker Symbol PPBT
Website https://purple-biotech.com
Analyst Forecast
According to 2 analyst ratings, the average rating for PPBT stock is "Buy." The 12-month stock price forecast is $126.5, which is an increase of 3375.27% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
-21.79%
Purple Biotech shares are trading lower after the ...
Unlock content with
Pro Subscription
1 month ago ·
Source
+150%
Purple Biotech shares are trading higher after the company announced final results from the randomized Phase 2 study of its lead oncology drug, CM24 in patients with pancreatic ductal adenocarcinoma.
